Last reviewed 2026-04-23 · How we verify

Memantine-XR

Memantine-XR is an extended-release formulation of memantine, an uncompetitive NMDA receptor antagonist that blocks excessive glutamate signaling in the brain.

Memantine-XR is an extended-release formulation of memantine, an uncompetitive NMDA receptor antagonist that blocks excessive glutamate signaling in the brain. Used for Moderate to severe Alzheimer's disease.

At a glance

Mechanism of action

Memantine acts as a non-competitive antagonist at the N-methyl-D-aspartate (NMDA) receptor, reducing excitotoxicity caused by excessive glutamate. The extended-release formulation allows for once-daily dosing, improving patient compliance compared to immediate-release memantine. This mechanism is thought to slow cognitive decline in neurodegenerative conditions by protecting neurons from glutamate-mediated damage.

Approved indications

• Moderate to severe Alzheimer's disease

Common side effects

• Dizziness
• Headache
• Constipation
• Confusion
• Hallucinations

Key clinical trials

• Memantine for Enhanced Stroke Recovery (EARLY_PHASE1)
• NTS-WBRT in Brain Metastases (PHASE2)
• SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study (PHASE2)
• Memantine XR and Pregabalin for Chemotherapy-Induced Peripheral Neuropathy
• Predicting Treatment Response to Memantine in Autism Using Magnetic Resonance Spectroscopy (EARLY_PHASE1)
• Long-term Safety and Tolerability of Idalopirdine (Lu AE58054) as Adjunctive Treatment to Donepezil in Patients With Mild-moderate Alzheimer's Disease (PHASE3)
• Galantamine and Memantine Combination for Cognitive Impairments in Schizophrenia (PHASE2)
• Cortical Metrics Assessment Outcome Measure Development in Autism With Memantine Treatment

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.